AstraZeneca’s Farxiga succeeds in phase 3 cardiovascular outcomes trial
Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) therapies for up to $2bn in upfront and milestone payments.
The expanded indication for the once-daily single inhaler triple therapy would enable use by patients not adequately treated by a long-acting muscarinic receptor antagonist (LAMA) and long-acting β2-agonist
THRUCOOL offers dedicated cold chain services to safeguard the integrity of pharmaceutical and healthcare shipments during air transportation. These include priority uplift and handling, quick ramp transfers at